Johnson & Johnson ROA 2006-2018 | JNJ

Current and historical return on assets (ROA) values for Johnson & Johnson (JNJ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Johnson & Johnson ROA for the three months ending June 30, 2018 was 13.66%.
Johnson & Johnson Annual ROA
2017 0.83
2016 11.71
2015 11.55
2014 12.52
2013 10.42
2012 8.66
2011 8.51
2010 12.96
2009 12.96
2008 15.25
2007 13.06
2006 15.67
2005 17.09
Johnson & Johnson Quarterly ROA
Q2 2018 2.55
Q1 2018 2.79
Q4 2017 -6.81
Q3 2017 2.42
Q2 2017 2.51
Q1 2017 3.05
Q4 2016 2.70
Q3 2016 3.04
Q2 2016 2.86
Q1 2016 3.27
Q4 2015 2.41
Q3 2015 2.52
Q2 2015 3.42
Q1 2015 3.36
Q4 2014 1.93
Q3 2014 3.60
Q2 2014 3.20
Q1 2014 3.55
Q4 2013 2.65
Q3 2013 2.35
Q2 2013 3.08
Q1 2013 2.88
Q4 2012 2.12
Q3 2012 2.21
Q2 2012 1.22
Q1 2012 3.37
Q4 2011 0.19
Q3 2011 2.86
Q2 2011 2.48
Q1 2011 3.21
Q4 2010 1.89
Q3 2010 3.48
Q2 2010 3.74
Q1 2010 4.84
Q4 2009 2.33
Q3 2009 3.65
Q2 2009 3.67
Q1 2009 4.07
Q4 2008 3.20
Q3 2008 3.77
Q2 2008 3.78
Q1 2008 4.18
Q4 2007 2.93
Q3 2007 3.24
Q2 2007 4.13
Q1 2007 3.52
Q4 2006 3.07
Q3 2006 4.51
Q2 2006 4.62
Q1 2006 5.32
Q4 2005 3.56
Q3 2005 4.49
Q2 2005 4.74
Q1 2005 5.21
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $376.840B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $257.521B 15.07
Novartis AG (NVS) Switzerland $196.752B 16.88
Merck (MRK) United States $188.679B 16.66
AbbVie (ABBV) United States $137.829B 13.46
Novo Nordisk (NVO) Denmark $114.846B 18.36
Eli Lilly (LLY) United States $113.563B 21.02
Sanofi (SNY) France $110.105B 13.94
Bristol-Myers Squibb (BMY) United States $99.380B 17.99
GlaxoSmithKline (GSK) United Kingdom $98.081B 13.10
AstraZeneca (AZN) United Kingdom $94.477B 10.39